<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37061281</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2173-5743</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Reumatologia clinica</Title><ISOAbbreviation>Reumatol Clin (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Relevance of non-criteria antiphospholipid antibodies titers among patients with antiphospholipid syndrome and patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>197</StartPage><EndPage>203</EndPage><MedlinePgn>197-203</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.reumae.2023.01.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2173-5743(23)00013-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is an increasing interest in the study of non-criteria antiphospholipid antibodies (aPL) including antibodies targeting domain 1 of the B2 glycoprotein 1 (anti-D1 B2GP1) and antibodies anti phosphatidylserine/ prothrombin (PS/PT).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Our aim was to analyze a panel of conventional and non-criteria aPL in a cohort of patients with systemic lupus erythematosus (SLE) and primary antiphospholipid syndrome (APS), to describe if there are differences in aPL titers among groups, to evaluate clinical associations including risk of recurrent events of novel aPL.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Observational study that evaluated at baseline antibodies against anti-D1 B2GP1 and anti PS/PT. Anti-D1 B2GP1 antibodies were tested using a chemiluminescent immunoassay. IgG and IgM anti PS/PT, aCL and anti B2GP1 by ELISA techniques. Therefore, patients were followed in order to identify new thrombotic events.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">133 patients with SLE and 23 with primary APS patients were included. Main APS manifestations were DVT (27%), obstetric morbidity (22%) and arterial thrombosis (10.1%). IgM anti PS/PT antibodies levels were (20.6 - 127) vs 21.9 (11.2 - 39.2) U/ml, p&lt;0.001 in primary APS vs SLE with APS, respectively. Anti-D1 B2GP1, IgG and IgM anti PS/PT were associated with thrombotic and non-thrombotic manifestations. During follow-up, IgG B2GP1 were related with a significant cumulative risk of thrombosis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found significant differences in serum titers of non-criteria aPL among patients with primary APS vs SLE with APS. Whether non-criteria aPL antibodies titers are useful to differentiate patients with primary and secondary APS requires further analysis in other populations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Published by Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Urrego-Callejas</LastName><ForeName>Tom&#xe1;s</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Grupo de Inmunolog&#xed;a Celular e Inmunogen&#xe9;tica, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz Giraldo</LastName><ForeName>Sebasti&#xe1;n</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frade-Sosa</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Servicio de Reumatolog&#xed;a, Hospital Cl&#xed;nic, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanegas-Garc&#xed;a</LastName><ForeName>Adriana L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Grupo de Reumatolog&#xed;a, Universidad de Antioquia y Hospital San Vicente Fundaci&#xf3;n, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz</LastName><ForeName>Carlos H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Grupo de Reumatolog&#xed;a, Universidad de Antioquia y Hospital San Vicente Fundaci&#xf3;n, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rua</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Grupo de Investigaci&#xf3;n en Trombosis, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duque Botero</LastName><ForeName>Julieta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez</LastName><ForeName>Luis A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Grupo de Reumatolog&#xed;a, Universidad de Antioquia y Hospital San Vicente Fundaci&#xf3;n, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;squez</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Grupo de Inmunolog&#xed;a Celular e Inmunogen&#xe9;tica, Universidad de Antioquia, Medell&#xed;n, Colombia; Departamento de Medicina Interna, Universidad de Antioquia, Medell&#xed;n, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Puerta</LastName><ForeName>Jos&#xe9; A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Servicio de Reumatolog&#xed;a, Hospital Cl&#xed;nic, Barcelona, Espa&#xf1;a. Electronic address: jagomez@clinic.cat.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Reumatol Clin (Engl Ed)</MedlineTA><NlmUniqueID>101717526</NlmUniqueID><ISSNLinking>2173-5743</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibodies</Keyword><Keyword MajorTopicYN="N">Anticuerpos</Keyword><Keyword MajorTopicYN="N">Antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">Lupus eritematoso sist&#xe9;mico</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">S&#xed;ndrome antifosfol&#xed;pido</Keyword><Keyword MajorTopicYN="N">Thrombosis</Keyword><Keyword MajorTopicYN="N">Trombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>15</Day><Hour>20</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37061281</ArticleId><ArticleId IdType="doi">10.1016/j.reumae.2023.01.001</ArticleId><ArticleId IdType="pii">S2173-5743(23)00013-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>